264 completed, 156 recruiting, 96 unknown, 86 terminated. 506 Phase 2, 268 Phase 1, 124 Phase 3, 11 Not applicable, 7 Phase 4.
Follow this drug Literature Review of 130-nm albumin-bound paclitaxel trials Research Report on 130-nm albumin-bound paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 125 | 2027-02-03 | 2026-08-06 |
| Evaluation of the Efficacy and Safety of Neoadjuvant Therapy in Patients With Surgically Resectable Pancreatic Adenocarcinoma. GnP, FOLFIRINOX - Pancreatic Adenocarcinoma Resectable, Non Metastatic | Phase 2 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 42 | 2027-01-01 | 2026-09-15 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer | Phase 2 | Not yet recruiting | Jun Gong, MD | 200 | 2026-12-01 | 2026-10-08 |
| PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | German Cancer Research Center | 406 | 2026-11-30 | 2026-10-16 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) MK-2010, Pembrolizumab, 5-Fluorouracil - Malignant Neoplam, Advanced Solid Tumors | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 480 | 2026-10-27 | 2026-10-08 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Disitamab Vedotin and Toripalimab, Toripalimab and Nab-Paclitaxel - Bladder (Urothelial, Transitional Cell) Cancer, Antibody-drug Conjugates | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | 150 | 2026-10-20 | 2026-10-16 |
| A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer Manganese Chloride, Nab-paclitaxel, Platinum chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Chinese PLA General Hospital | 120 | 2026-10-12 | 2026-09-16 |
| Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma Rimegepant, Tislelizumab, Nab-paclitaxel - Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 220 | 2026-10-01 | 2026-09-10 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | caohaotian | 300 | 2026-10-01 | 2026-09-18 |
| Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy - Pancreatic Cancer | Phase 2 | Not yet recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 20 | 2026-10-01 | 2026-10-13 |
| Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer Relacorilant, Nab-paclitaxel - Recurrent or Metastatic Cervical Cancer | Phase 2 | Not yet recruiting | ARCAGY/ GINECO GROUP | 63 | 2026-10-01 | 2026-08-13 |
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 45 | 2026-09-10 | 2026-09-03 |
| Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin - ESCC | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 33 | 2026-09-10 | 2026-09-09 |
| A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel - Triple-Negative Breast Cancer (TNBC) | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 436 | 2026-09-02 | 2026-09-30 |
Showing 20 of 794. Sign in to see all of them.
Pancreatic Neoplasms (205) · Breast Neoplasms (112) · Carcinoma, Non-Small-Cell Lung (102) · Triple Negative Breast Neoplasms (68) · Neoplasm Metastasis (49) · Neoplasms (45) · Lung Neoplasms (26) · Squamous Cell Carcinoma of Head and Neck (26) · Esophageal Squamous Cell Carcinoma (21) · Colorectal Neoplasms (19) · Adenocarcinoma (17) · Stomach Neoplasms (17) · Head and Neck Neoplasms (16) · Melanoma (15) · Ovarian Neoplasms (13)
ImmunityBio, Inc. (22) · M.D. Anderson Cancer Center (21) · Merck Sharp & Dohme LLC (21) · Fudan University (20) · Hoffmann-La Roche (17) · Celgene (16) · Tianjin Medical University Cancer Institute and Hospital (13) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (11) · AstraZeneca (10) · Bristol-Myers Squibb (10) · National Cancer Institute (NCI) (10) · Chinese PLA General Hospital (9) · Washington University School of Medicine (9) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Gilead Sciences (8)
United States (395) · China (263) · Spain (111) · Germany (87) · France (83) · Italy (82) · Australia (74) · South Korea (74) · Canada (67) · United Kingdom (66) · Japan (64) · Taiwan (57) · Belgium (52) · Poland (45) · Brazil (44)
Jared Weiss, MD (6) · Erwei Song, M.D., Ph.D. (3) · Guopei Luo, MD (3) · Peng Zhang, PhD (3) · Ana De Jesus-Acosta, MD (2)
PMID 32450725, PMID 34252375, PMID 31401903, PMID 35511917, PMID 37364223, PMID 37499870, PMID 38050737, PMID 12049861, PMID 22547591, PMID 24703985, PMID 24885187, PMID 25476537, PMID 25579459, PMID 25679067, PMID 25845992, PMID 25961845, PMID 26056183, PMID 26201606, PMID 26254683, PMID 26698868, PMID 26808342, PMID 26869049, PMID 27000274, PMID 27244882, PMID 27404453, PMID 27701653, PMID 27840089, PMID 27876675, PMID 28114604, PMID 28179342, PMID 28315068, PMID 28620884, PMID 28701571, PMID 28797458, PMID 28869790, PMID 28918548, PMID 28939558, PMID 29119276, PMID 29158367, PMID 29190925, PMID 29228091, PMID 29232172, PMID 29273007, PMID 29327055, PMID 29346519, PMID 29409469, PMID 29438178, PMID 29441562, PMID 29691300, PMID 29695765
2023 (18), 2016 (12), 2025 (12), 2014 (11), 2017 (8), 2018 (8), 2019 (8), 2015 (7), U10CA180820 (5), P30CA138292 (4), P30CA033572 (3), U10CA180868 (3), U10CA180888 (3), P30CA015083 (2), P30CA015704 (2)